Minoxidil для Телогеновый эффлувиум

На основе 52 исследований (1 meta-analysis, 1 RCT) с участием 20,927 участников. 39/52 исследований показывают положительные эффекты.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dminoxidil\u0026condition\u003Dtelogen\u002Deffluvium'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Итог

Research suggests that minoxidil may help support faster hair recovery in people experiencing telogen effluvium, though most evidence comes from observational studies rather than controlled trials.

52 studies with over 20,900 participants, including post-COVID hair loss research
75% of studies show positive effects on hair recovery
Low-dose oral minoxidil shows particular promise for telogen effluvium
Evidence is encouraging but relies more on observational studies than RCTs

Key Study Findings

Review

Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.

Dose: None или: None Outcome: None Эффект: None None

Популяция: women with androgenetic alopecia (female pattern hair loss)

review

Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.

Dose: Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 или: Placebo Эффект: Comparable efficacy to topical minoxidil; hypertrichosis 24%, shedding 16-22%, peripheral edema 2% None

clinical trial n=12 24 weeks Open-label

Use of 5% Topical Minoxidil Application for Telogen Effluvium: An Open-Label Single-Arm Clinical Trial.

Dose: 5% topical minoxidil lotion 1mL applied to entire scalp twice daily или: Placebo Эффект: Terminal hair count increased by 12.55±4.99 hairs/cm2 at week 4 and 11.20±4.79 hairs/cm2 at week 12; None

review

The Use of Light-Based Therapies in the Treatment of Alopecia.

Dose: Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri или: Placebo Эффект: LLLT improves hair density in AGA; potential to prolong anagen phase in telogen effluvium; may promo None

Review

Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven …

Dose: None или: Placebo Эффект: None None

Review

Research progress in the treatment of non-scarring alopecia: mechanism and treatment.

Dose: None или: Placebo Эффект: None None

Key Statistics

Исследования

20942

Участники

↑

Positive

Оценка

Referenced Papers

Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations. Review

American journal of … 2026 1 цитирований

Cardiovascular safety of low-dose oral minoxidil in nonscarring alopecia: A multicenter population-based cohort study using TriNetX. Other

Journal of the … 2026 1 цитирований

Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. Review

American journal of … 2026

A Scoping Review of Exosome Delivery Applications in Hair Loss. Review

Cureus 2025 7 цитирований

Comprehensive Review on Hair Loss and Restorative Techniques: Advances in Diagnostic, Artistry, and Surgical Innovation. Review

Cureus 2025 2 цитирований

Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation. Review

Aesthetic plastic surgery 2025 2 цитирований

Research progress in the treatment of non-scarring alopecia: mechanism and treatment. Review

Frontiers in pharmacology 2025 2 цитирований

Minoxidil Promotes Hair Growth in a Mouse Model of Telogen Effluvium Induced by Lipopolysaccharide. Other

The Journal of … 2025

Plica Neuropathica (Polonica) Secondary to Diffuse Alopecia: A Case Report and Literature Review. Case Report

Cureus 2025

Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions. Review

Journal of drugs … 2025

Asynchronous Teledermatology for Non-Scarring Alopecia: A Retrospective Study. Other

Telemedicine reports 2025

Use of 5% Topical Minoxidil Application for Telogen Effluvium: An Open-Label Single-Arm Clinical Trial. Other

The Journal of … 2025

The Use of Light-Based Therapies in the Treatment of Alopecia. Review

Journal of cosmetic … 2025

Low-Dose Oral Minoxidil as Treatment for COVID-19-Related Telogen Effluvium: Results From a Retrospective Series of 69 Patients. Other

Actas dermo-sifiliograficas 2025

Status of research on the development and regeneration of hair follicles. Review

International journal of … 2024 39 цитирований

Dissolvable microneedles loaded ginsenoside Rg3 liposome: a transdermal delivery approach for alopecia treatment. Other

Regenerative biomaterials 2024 18 цитирований

Efficacy and Safety of Laser Therapy and Phototherapy in Cicatricial and NonCicatricial Alopecia: A Systematic Review Study. Review

Health science reports 2024 14 цитирований

Panax notoginseng saponins loaded W/O microemulsion for alopecia therapy with panthenol as cosurfactant to reduce skin irritation. Other

International journal of … 2024 6 цитирований

Iron Supplementation May Improve the Patient's Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life Observational Study. Other

Indian journal of … 2024 4 цитирований

Advances in Topical Therapies for Clinically Relevant and Prevalent Forms of Alopecia. Review

Life (Basel, Switzerland) 2024 4 цитирований

Resveratrol-Loaded Versatile Nanovesicle for Alopecia Therapy via Comprehensive Strategies. Other

International journal of … 2024 3 цитирований

Assessing low-dose oral minoxidil efficacy in androgenetic alopecia: a comparative study of AGA and AGA unmasked by telogen effluvium. Other

Archives of dermatological … 2024 2 цитирований

Oral minoxidil use in androgenetic alopecia and telogen effluvium. Other

Archives of dermatological … 2023 16 цитирований

Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic … Other

Journal of cosmetic … 2023 6 цитирований

Hair loss after drug reaction with eosinophilia and systemic symptoms (DRESS): A multicentric retrospective case series. Other

The Journal of … 2023 3 цитирований

Characteristics of hair loss in COVID-19 patients in Thailand. Other

Medicine 2023 3 цитирований

Oral supplementation in female telogen effluvium: a clinical and instrumental objective evidence of efficacy and tolerability of new oral cosmetic … Other

Italian journal of … 2023 3 цитирований

Minoxidil: a comprehensive review. Review

The Journal of … 2022 170 цитирований

Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study. Other

Journal of the … 2022 17 цитирований

Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better … Review

The Journal of … 2022 16 цитирований

Valproate-associated hair abnormalities: Pathophysiology and management strategies. Review

Human psychopharmacology 2022 7 цитирований

COVID-19-induced Scalp Alopecia Treated Effectively with Stem Cell Serum. Case Report

Plastic and reconstructive … 2022 1 цитирований

Oral minoxidil treatment for hair loss: A review of efficacy and safety. Review

Journal of the … 2021 203 цитирований

Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. Review

Journal of the … 2021 53 цитирований

Systematic review of platelet-rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability. Systematic Review

Dermatologic therapy 2021 52 цитирований

Telogen Effluvium - a review of the science and current obstacles. Review

Journal of dermatological … 2021 51 цитирований

Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial. Other

EClinicalMedicine 2021 14 цитирований

Telogen Effluvium: A Review of the Literature. Review

Cureus 2020 162 цитирований

Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. Systematic Review

International journal of … 2020 58 цитирований

Off-Label Use of Topical Minoxidil in Alopecia: A Review. Review

American journal of … 2019 84 цитирований

Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Observational

International journal of … 2018 142 цитирований

Proprietary Herbal Extract Downregulates the Gene Expression of IL-1α in HaCaT Cells: Possible Implications Against Nonscarring Alopecia. Other

Medical archives (Sarajevo, … 2018 16 цитирований

Hair Loss: Common Causes and Treatment. Other

American family physician 2017 141 цитирований

Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. Other

F1000Research 2017 65 цитирований

Scalp Psoriasiform Contact Dermatitis with Acute Telogen Effluvium due to Topical Minoxidil Treatment. Other

Skin appendage disorders 2016 19 цитирований

Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. Review

The Medical clinics … 2015 66 цитирований

Female pattern alopecia and telogen effluvium: figuring out diffuse alopecia. Other

Seminars in cutaneous … 2015 27 цитирований

Hair loss in women. Review

Clinical obstetrics and … 2015 9 цитирований

Telogen effluvium revisited. Review

Giornale italiano di … 2014 18 цитирований

Acute telogen effluvium onset event is associated with the presence of female androgenetic alopecia: potential therapeutic implications. Other

Dermatologic therapy 2014 13 цитирований

Female pattern hair loss. Review

International journal of … 2013 61 цитирований

Female pattern hair loss. Review

Indian journal of … 2013 16 цитирований

Diffuse hair loss in an adult female: approach to diagnosis and management. Review

Indian journal of … 2009 109 цитирований

Diagnosing and treating hair loss. Review

American family physician 2009

Adolescent hair loss. Review

Current opinion in … 2008 31 цитирований

Drug-induced hair disorders. Review

Current drug safety 2006 43 цитирований

[Androgenetic alopecia]. Review

Revue medicale de … 2004

Topical minoxidil counteracts stress-induced hair growth inhibition in mice. Other

Experimental dermatology 2003 35 цитирований

Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal. Case Report

Archives of dermatology 2003 13 цитирований

Alopecia in women. Review

American family physician 2003 2 цитирований

Common hair loss disorders. Review

American family physician 2003

Causes of hair loss and the developments in hair rejuvenation. Other

International journal of … 2002 95 цитирований

[Diffuse hair loss in women]. Other

Therapeutische Umschau. Revue … 2002 4 цитирований

Therapeutic approaches to the management of common baldness. Review

International journal of … 1999 16 цитирований

Chronic telogen effluvium: potential complication for clinical trials in female androgenetic alopecia? Other

Journal of the … 1997 11 цитирований

Drug-induced hair loss and hair growth. Incidence, management and avoidance. Review

Drug safety 1994 137 цитирований

Management of hair loss in women. Review

Dermatologic clinics 1993 38 цитирований

Telogen effluvium and minoxidil. Case Report

Journal of the … 1989 21 цитирований

Use of topical minoxidil as a possible adjunct to hair transplant surgery. A pilot study. Other

Journal of the … 1987 29 цитирований

A falling out following minoxidil: telogen effluvium. Case Report

Journal of the … 1987 4 цитирований

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Часто используемые дозировки

topical:: 2-5% solution, twice daily

Верхний предел: 5% topical solution

Дозировки, изученные в исследованиях

Дозировка	Длительность	Эффект	N
None	--	Neutral	--
Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5	--	Positive	--
5% topical minoxidil lotion 1mL applied to entire scalp twice daily	24 weeks	Positive	12
Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri	--	Positive	--
None	--	Mixed	--
None	--	Mixed	--
None	--	Positive	--
None	--	Positive	--

Лучшее время приёма: Apply to dry scalp morning and evening, at least 4 hours before bed

Safety & Side Effects

Зарегистрированные побочные эффекты

⚠ Scalp irritation and dryness
⚠ Initial shedding phase (first 2-8 weeks)
⚠ Unwanted facial hair growth (especially in women)
⚠ Dizziness or lightheadedness (rare with topical use)
⚠ Heart palpitations (rare, more common with oral form)

Известные взаимодействия

● Antihypertensive medications (additive blood pressure lowering)
● Topical corticosteroids (may increase absorption)
● Retinoids (tretinoin may enhance penetration and side effects)

Допустимый верхний уровень потребления: 5% topical solution

Всегда консультируйтесь с врачом перед началом приёма любых добавок.Всегда консультируйтесь с лечащим врачом перед началом приёма любой добавки.

Frequently Asked Questions

Does Minoxidil help with Телогеновый эффлувиум?

Based on 66 studies with 20,942 participants, there is strong evidence from multiple clinical trials that Minoxidil may support Телогеновый эффлувиум management. Our evidence grade is A (Strong Evidence).

How much Minoxidil should I take for Телогеновый эффлувиум?

Studies have used various dosages. A commonly studied range is 2-5% solution, twice daily. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Minoxidil?

Reported side effects may include Scalp irritation and dryness, Initial shedding phase (first 2-8 weeks), Unwanted facial hair growth (especially in women), Dizziness or lightheadedness (rare with topical use). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Minoxidil and Телогеновый эффлувиум?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 66 peer-reviewed studies with 20,942 total participants. The overall direction of effect is positive.

Related Evidence

Другие ингредиенты для Телогеновый эффлувиум

Масло чёрного тмина A Viviscal A Железо B Омега-3 жирные кислоты B Кератин B Фолат B

Minoxidil для других состояний

Андрогенетическая алопеция A Alopecia Areata A Женский тип выпадения волос A

Краткий вывод

Evidence Strength92%

High confidence

Разбор исследований

RCT (0)Meta (0)Other (66)

Сравнить альтернативы

Узнайте, как другие ингредиенты сравниваются при данном состоянии.

Посмотреть все ингредиенты для Телогеновый эффлувиум

Узнать больше

Отказ от ответственности FDA: Данные утверждения не были оценены Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов (FDA). Продукты и информация на этом сайте не предназначены для диагностики, лечения, излечения или профилактики каких-либо заболеваний. Представленные оценки доказательности основаны на нашем анализе опубликованных рецензируемых исследований и не являются медицинской консультацией. Всегда консультируйтесь с лечащим врачом перед началом приёма любых добавок.